A cholesterol prescription and an osteoporosis prescription answer different clinical questions. New research suggests the biology behind them may overlap, especially after menopause, but it has not shown that statins prevent broken bones.
A study published in Nature Aging on October 27 combines medical-record analyses in 169 postmenopausal women with experiments tracing how bone-forming cells respond to atorvastatin. Its most interesting contribution is a possible explanation for why hormonal state might change the skeleton’s response to a widely used drug.
Evidence type: Human Observational and Preclinical Research. The human bone-density findings are retrospective associations. The intervention and mechanism experiments were performed in mice and cultured cells.
Two hospital cohorts, three comparison groups
The researchers studied women aged 55 to 65 who had been postmenopausal for at least three years. Each had at least two lumbar-spine DXA scans separated by six months or more. DXA measures bone mineral density, the amount of mineral within the scanned bone area.
The Beijing Jishuitan Hospital cohort included 80 women: 27 statin users, 17 evolocumab users and 36 controls taking no lipid-lowering therapy. The independent Kowloon Hospital cohort in Suzhou included 89: 25 statin users, 15 evolocumab users and 49 controls. Thus, the study involved two cohorts, not just two treatment groups.
Statin use was associated with a slower annual decline in lumbar-spine bone mineral density in both cohorts. Evolocumab, which lowers cholesterol through a different mechanism, did not show the same association. The investigators used dispensing and administration records to classify continuous treatment during the interval between scans.
The records covered different follow-up intervals, reaching a maximum of 78 months in Beijing and 53 months in Suzhou. The paper reports statistical comparisons of annualized density changes; those findings should not be converted into a percentage reduction in fractures.
Why estrogen deficiency led the researchers to stem cells
Bone is continually remodeled: some cells remove old tissue while osteoblasts build new bone. After menopause, changes in estrogen signaling can disturb this balance. The new work focuses on an earlier stage, the marrow cells that supply bone-forming cells.
These LEPR-positive stromal cells carry the leptin receptor and include skeletal stem and progenitor cells. In mouse fate-mapping experiments, researchers genetically labeled the population and followed its descendants rather than inferring cell origins from bone density alone.
Atorvastatin increased bone formation and bone mass in aged female mice and females whose ovaries had been removed to model estrogen deficiency. Comparable benefits were not detected in young adult mice or aged males. Key bone-mass comparisons used six animals per treatment group, while cell-origin experiments commonly used five.
Cultures derived from mouse marrow and human donor marrow also showed increased development toward bone-forming cells. Human cells responding in a dish provide mechanistic evidence, but they do not turn the medical-record analysis into a human treatment trial.
A different route to a shared growth signal
The experiments place osteolectin, a protein that promotes bone formation, at a convergence point. Estrogen signaling through its receptor increased transcription of the osteolectin gene. Atorvastatin reached that gene through a different route.
Statins inhibit the mevalonate pathway. Besides supplying cholesterol synthesis, this pathway supplies lipid components used in prenylation, a modification that helps proteins function and locate within cells. The researchers linked restricted RAC1 prenylation to increased RAC1 activity and recruitment of NF-κB to the osteolectin gene.
Deleting Rac1 in the relevant mouse marrow cells, or removing osteolectin, weakened the bone-building response. These interventions strengthen the mechanistic case in the experimental models. They do not establish that this entire sequence explains the association in the women.
What would make this a treatment finding
The women were not randomly assigned to statins. Differences in health, medical care, lifestyle and the reasons for prescribing a drug could influence both treatment and bone outcomes. Similar measured baseline characteristics and a second cohort help, but cannot eliminate unmeasured confounding.
The study did not demonstrate fewer fractures. Density is relevant to fracture risk, but the outcomes are not interchangeable. Fractures also depend on bone structure, falls and other factors. The authors acknowledge that earlier randomized and pooled evidence has not shown a consistent fracture-prevention effect.
That distinction also runs through our examination of metformin’s proposed uses beyond its original indication: an interesting pathway needs clinical outcome evidence.
A prospective randomized study would need to test an appropriate statin, dose and duration in a clearly defined population, assess adverse effects and establish whether any density benefit translates into fewer fractures. The results do not justify starting or changing a statin for osteoporosis, or substituting it for established bone-directed treatment.
Original research and scope
Yang M, Guo J, Ye J and colleagues. Statins promote bone anabolism in estrogen deficiency by inducing osteogenic differentiation of skeletal stem/progenitor cells. Nature Aging. Published October 27, 2026. The accessible full text, methods, results, main and extended-data legends and discussion were reviewed. Numerical density values were not independently recalculated from source-data spreadsheets. Original reporting based on a source article licensed under CC BY 4.0.
Featured image: AI-generated conceptual illustration, not experimental microscopy.